Abstract
PET imaging is having a major impact in patient care. The increasing utilization of PET is related to several major factors: clinical data demonstrating the usefulness, reimbursement, availability of instrumentation and distribution of FDG. We are just beginning to see the “tip of the iceberg” in the clinical and research utilization of PET. PET is a molecular imaging technique, and PET imaging will be the major imaging modality of molecular medicine. The ability to label molecules with positron-emitting radionuclides and quantitatively determine their distribution will be important in disease characterization, drug discovery, drug therapy and gene therapy [8]. These uses will frequently begin with the mouse, which is the animal most widely used in drug development and in gene therapy. Systems such as the microPET permit high resolution (1-2 mm) of PET tracers in small animals including mice [2, 12]. These studies can then be performed in adult subjects to verify the results obtained in animals. The ethical drug industry is beginning to adapt this technology in their developmental efforts.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Al-Aish M, Coleman RE, Larson SM, et al. (1990) Advances in clinical imaging using positron emission tomography. National Cancer Institute Workshop Statement. Arch Int Med 150:735–739
Chatziioannou AF, Cherry SR, Shao Y, et al. (1999) Performance evaluation of micro-PET: a high-resolution lutetium oxyorthosilicate PET scanner for animal imaging. J Nucl Med 40(7):1164–1175
Coleman RE (1997) Editorial: Camera-based PET: the best is yet to come. J Nucl Med 38(11):1796–1797
Coleman RE (1998) Clinical PET in oncology. Clinical Positron Imaging 1:15–30
Coleman RE, Tesar RD (2000) A perspective on clinical PET imaging. Clin Pos Imag 3:41–44
Coleman RE, Robbins MS, Siegel BA (1992) The future of PET in clinical medicine and the impact of drug regulation. Semin Nucl Med 12:193–201
Kuhl DE, Wagner HN, Alavi A, Coleman RE, Larson SM, Mintun MA, Siegel BA, Strudler PK (1988) Positron emission tomography (PET): Clinical status in the United States in 1987. J Nucl Med 29:1136–1143
Phelps ME, Coleman RE (2000) Editorial: Nuclear medicine in the new millennium. J Nucl Med 41:1–4
Phelps ME, Hoffman EJ, Coleman RE, Welch MJ, Raichle ME, Weiss ES, Sobel BE, TerPogossian MM (1976) Tomographic images of blood pool and perfusion in brain and heart. J Nucl Med 17:603–612
Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM (1975) Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med 16:210–224
Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (1991) (Panel members: Mazziotta J, Coleman RE, Di Chiro G, Foster N, Fox P, Frackowiak R, Gilman S, Martin W, Raichle M, Theodore W) Assessment: Positron emission tomography. Neurology 41:163–167
Tornai MP, Jaszczak RJ, Turkington TG, Coleman RE (1999) Editorial: Small-animal PET: advent of a new era of PET research. J Nucl Med 40:1176–1179
Wieler HJ (1999) PET in der klinischen Onkologie. Steinkopff Verlag, Darmstadt
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Coleman, R.E., Wieler, H.J. (2000). Current status of PET in the United States. In: Wieler, H.J., Coleman, R.E. (eds) PET in Clinical Oncology. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57703-1_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-57703-1_1
Publisher Name: Steinkopff, Heidelberg
Print ISBN: 978-3-642-63329-4
Online ISBN: 978-3-642-57703-1
eBook Packages: Springer Book Archive